Description du projet
Un test d’allergie basé sur les nanotechnologies
Près d’une personne sur dix développe une allergie aux bêta-lactamines, la classe d’antibiotiques la plus courante. La méthode actuelle de diagnostic de l’allergie aux bêta-lactamines est le test cutané classique, qui peut toutefois présenter des effets indésirables. Le projet ASSERT, financé par l’UE, vise à faire du test d’activation des basophiles (BAT) une méthode de diagnostic de routine de l’allergie aux bêta-lactamines. Le BAT mesure l’activation des basophiles, médiateurs des réactions allergiques, qui libèrent de l’histamine après avoir été stimulés par un allergène. Les chercheurs auront recours aux nanotechnologies pour améliorer la précision et la reproductibilité du test BAT et le valider en vue d’une utilisation clinique de routine.
Objectif
Betalactams (BL) are the most widely used antibiotics and the first-choice drugs to control several bacterial infections, however, they can lead to serious allergic reactions in up to 10% of the general population. The current diagnosis of allergy to BL includes skin test and/or drug provocation tests, which are invasive and carry a risk of anaphylaxis requiring hospitalisation. Basophil activation test (BAT) is one of the best options for diagnosis of allergy because it is free of risk and at a reduced cost for health care. The ASSERT project will bring a nanotechnology-based BAT assay specific for allergy to BL with higher sensitivity and specificity, which are the main weakness of the current assays. Of importance, the number and conformation of displayed antigens at the nanoparticle surface will be controlled to assure standardisation and increase precision and reproducibility of the assay. In addition, a complete validation plan is envisaged to fit the standards for clinical diagnostics. The two factors for the success of the project are, one one hand, the solid experience of the host lab in immunology, specially allergy and nanoparticle technology and, on the other hand, the expertise of the candidate in immunology, molecular biology and test validation design for clinical diagnostics. Moreover, the the two way of transfer of knowledge is assured, which will help the candidate to restart her research career in the European Union. Finally, the expected results of the project will contribute to enlarge the basic knowledge about allergen-specific activation of basophils, and will give rise to an optimised BL-BAT assay with the required clinical and analytical validation to be used in diagnostics.
Champ scientifique
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesclinical medicineallergology
- engineering and technologynanotechnologynano-materials
- natural sciencesbiological sciencesmolecular biology
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
29590 MALAGA
Espagne